- Country: USA
- Summary: KIT COBAS 58/68/8800 HIV 192T IVD and related control reagents through Roche Diagnostics
- UST Ref No: 118544035
- Deadline: 06 May 2025
- Financier: Self Financed
- Purchaser Ownership: Government
- Tender Value: Refer Document
- Notice Type: Tender
- Document Ref. No.: NOI-NIAID-25-2260950
- Purchaser's Detail:Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
- Description:
- Description
PRE-SOLICITATION NOTICE **NOTICE OF INTENT TO SOLE SOURCE
NOI-NIAID-24-2260950
NAICS - 325414
This is a Notice of Intent, not a request for proposal. The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) intends to negotiate on an other than full and open competition basis with Roche Diagnostics Corporation to provide:
KIT COBAS 58/68/8800 HIV 192T IVD, Catalog# 9040803190, Quantity 17 EA (to be delivered over 8 shipments between June 2025 - Feb 2026) Shipping/Handling fees to Bethesda, MDThe Laboratory of Immunoregulation (LIR) focuses its research efforts on the elucidation of cellular and molecular mechanisms of the regulation of the human immune response in health and disease. A major component of these efforts is focused on the study of the mechanisms of viral persistence in human immunodeficiency virus (HIV) infected individuals receiving antiretroviral therapy (ART). The advent of ART has dramatically improved the clinical outcome in HIV-infected individuals through sustained reduction in viral replication. However, it has become clear that ART alone cannot eradicate HIV in infected individuals, likely in part due to the persistence of viral reservoirs in peripheral blood and various tissue compartments. Consequently, a major thrust of HIV research over the past several years has been to develop therapeutic strategies that can eliminate persistent viral reservoirs and boost host immunity to control viral replication upon discontinuation of ART. Given lack of efficacy and difficulties encountered with modalities, such as HIV purging agents and chemotherapy and stem cell transplantation, a more realistic approach is needed to explore the therapeutic strategies that harness host immunity to control HIV replication in infected individuals in the absence of ART. To that end, the LIR requires 17 kits of COBAS 58/68/8800 HIV 192T IVD and related control reagents from Roche Diagno... - Documents:
If you are registered member, kindly login to view full details of this tender notice:
CLICK HERE TO LOGINKIT COBAS 58/68/8800 HIV 192T IVD and related control reagents through Roche Diagnostics - USA Tender
The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | NATIONAL INSTITUTES OF HEALTH, a Government sector organization in USA, has announced a new tender for KIT COBAS 58/68/8800 HIV 192T IVD and related control reagents through Roche Diagnostics. This tender is published on USARFP under UST Ref No: 118544035 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-05-06.
The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.
